Therapeutic Monoclonal Antibodies and Antibody Products, Their Optimization and Drug Design in Cancers (Record no. 29818)

MARC details
000 -LEADER
fixed length control field 01901nam a2200133Ia 4500
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 220620s9999||||xx |||||||||||||| ||und||
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 9783040000000
245 #0 - TITLE STATEMENT
Title Therapeutic Monoclonal Antibodies and Antibody Products, Their Optimization and Drug Design in Cancers
546 ## - LANGUAGE NOTE
Language note English[eng]
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element monoclonal antibody||NSCLC||immunotherapy||ELISA||pharmacokinetics||pharmacogenetics||anti-PD-1 monoclonal antibodies||anti-acetylcholine receptor (AChR) antibody||B cell||immune checkpoint blockade||immune-related adverse events (irAEs)||myasthenia gravis (MG)||non-small-cell lung cancer (NSCLC)||nivolumab||programmed cell death ligand 1 (PD-L1)||T cell||tetraspanins||cancer||Tspan8||radioimmunotherapy||immune-checkpoint inhibitors||LDH||biomarkers||Ang-2||antiangiogenic therapy||in vivo imaging||radio- and chemotherapy||VEGF-A||cancer therapy||neovascularization||angiogenesis||tumor microenvironment||colorectal cancer||antibody||NK cells||ADCC||CD133||prominin-1||gold nanoparticles||antibody-drug conjugates||cell penetrating peptide||HIV-1 TAT||active-targeting||targeted delivery||trastuzumab||MMAE||valine-citrulline||affibody||drug conjugates||hepatic uptake||DM1||dermatooncology||immune checkpoints||monoclonal antibodies||passive immunotherapy||canine B-cell lymphoma||DLA-DR||HLA-DR||antibody-drug conjugate||ADC||methotrexate||tumor immunity||combination therapy||multiple myeloma (MM)||monoclonal antibodies (mAbs)||antibody products||B cell maturation antigens (BCMAs)||bispecific T cell engagers (BiTEs®)||checkpoint inhibitors 1||protein structure 2||pharmacokinetics 3||drug optimization 4||HER2-positive breast cancer||metastatic disease||neoadjuvant and adjuvant therapy||targeted therapy||acute myeloid leukemia||CD123||IL3RA||kinesin spindle protein inhibitor
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Kayser, Veysel
856 ## - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier <a href="https://mdpi.com/books/pdfview/book/4898">https://mdpi.com/books/pdfview/book/4898</a>
942 ## - ADDED ENTRY ELEMENTS (KOHA)
Koha item type E-Books
Holdings
Withdrawn status Lost status Damaged status Not for loan Home library Current library Date acquired Total Checkouts Date last seen Price effective from Koha item type
        Kerala University of Digital Sciences, Innovation and Technology Knowledge Centre Kerala University of Digital Sciences, Innovation and Technology Knowledge Centre 20/06/2022   20/06/2022 20/06/2022 E-Books